TECH Stock Analysis: Bio-Techne | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.413m USD | 12M Return: 19.4% | US09073M1045 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 195M
EPS Trend: 1.5%
Qual. Beats: 1
Rev. Trend: 92.3%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bio-Techne Corporation (NASDAQ: TECH) is a Minneapolis, Minnesota-based life sciences company that develops, manufactures, and sells reagents, instruments, and services for the research, diagnostics, and bioprocessing markets globally. Founded in 1976 and formerly known as Techne Corporation, the company operates through two reportable segments: Protein Sciences, which supplies biological reagents (such as cytokines, growth factors, antibodies, small molecules, and cell selection technologies) along with proteomic analytical tools for automated western blot and multiplexed ELISA workflows; and Diagnostics and Spatial Biology, which produces diagnostic controls, calibrators, in-situ hybridization assays for tissue-based genomic analysis, and genetic and oncology kits for research and clinical use.
As a constituent of the Life Sciences Tools & Services sub-industry, Bio-Techne operates a hybrid business model combining proprietary reagent consumables with capital instruments, a structure that typically produces a meaningful share of recurring revenue from repeat reagent purchases. Its products serve a diversified customer base across academic research, biopharmaceutical development, regulated clinical diagnostics, and emerging cell and gene therapy applications.
- Protein Sciences segment revenue growth driven by cell and gene therapy demand
- Spatial Biology expansion through Lunaphore acquisition accelerates diagnostics growth
- Margin pressure persists amid acquisition integration costs and tariff exposure
| Net Income: 181.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.15 > 1.0 |
| NWC/Revenue: 47.79% < 20% (prev 35.46%; Δ 12.34% < -1%) |
| CFO/TA 0.11 > 3% & CFO 292.1m > Net Income 181.9m |
| Net Debt (113.5m) to EBITDA (343.4m): 0.33 < 3 |
| Current Ratio: 4.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.0m) vs 12m ago 0.80% < -2% |
| Gross Margin: 65.77% > 18% (prev 64.80%; Δ 0.97% > 0.5%) |
| Asset Turnover: 47.24% > 50% (prev 47.68%; Δ -0.45% > 0%) |
| Interest Coverage Ratio: 21.88 > 6 (EBIT TTM 246.1m / Interest Expense TTM 11.2m) |
| A: 0.22 (Total Current Assets 744.4m - Total Current Liabilities 163.7m) / Total Assets 2.59b |
| B: 0.44 (Retained Earnings 1.14b / Total Assets 2.59b) |
| C: 0.10 (EBIT TTM 246.1m / Avg Total Assets 2.57b) |
| D: 4.41 (Book Value of Equity 2.11b / Total Liabilities 478.5m) |
| Altman-Z'' = 8.18 = AAA |
| DSRI: 1.05 (Receivables 216.6m/206.9m, Revenue 1.22b/1.22b) |
| GMI: 0.99 (GM 64.80% / 65.77%) |
| AQI: 0.94 (AQ_t 0.60 / AQ_t-1 0.64) |
| SGI: 1.00 (Revenue 1.22b / 1.22b) |
| TATA: -0.04 (NI 181.9m - CFO 292.1m) / TA 2.59b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of November 04, 2026, the stock is trading at USD 72.66 with a total of 3,511,852 shares traded. Over the past week, the price has changed by +0.08%, over one month by +0.11%, over three months by +0.94% and over the past year by +19.41%.
Current recommended Stop Loss: 72.40 (which is 0.4% or 2 ATR below the current price).
Bio-Techne has received a consensus analysts rating of 2.85. Therefore, it is recommended to hold TECH.
- StrongBuy: 0
- Buy: 0
- Hold: 12
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 70.5 | -3% |
P/E Trailing = 62.6466
P/E Forward = 35.5872
P/S = 9.3933
P/B = 5.4129
P/EG = 2.1727
Revenue TTM = 1.22b USD
EBIT TTM = 246.1m USD
EBITDA TTM = 343.4m USD
Long Term Debt = 200.0m USD (from longTermDebt, last quarter)
Short Term Debt = 14.9m USD (from shortTermDebt, last quarter)
Debt = 378.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 89.1m
Net Debt = 113.5m USD (calculated: Debt 378.2m - CCE 264.7m)
Enterprise Value = 11.5b USD (11.4b + Debt 378.2m - CCE 264.7m)
Interest Coverage Ratio = 21.88 (Ebit TTM 246.1m / Interest Expense TTM 11.2m)
EV/FCF = 43.79x (Enterprise Value 11.5b / FCF TTM 263.2m)
FCF Yield = 2.28% (FCF TTM 263.2m / Enterprise Value 11.5b)
FCF Margin = 21.66% (FCF TTM 263.2m / Revenue TTM 1.22b)
Net Margin = 14.97% (Net Income TTM 181.9m / Revenue TTM 1.22b)
Gross Margin = 65.77% ((Revenue TTM 1.22b - Cost of Revenue TTM 416.0m) / Revenue TTM)
Gross Margin QoQ = 65.82% (prev 66.88%)
Tobins Q-Ratio = 4.46 (Enterprise Value 11.5b / Total Assets 2.59b)
Interest Expense / Debt = 2.97% (Interest Expense 11.2m / Debt 378.2m)
Taxrate = 24.44% (58.8m / 240.7m)
NOPAT = 185.9m (EBIT 246.1m * (1 - 24.44%))
Current Ratio = 4.55 (Total Current Assets 744.4m / Total Current Liabilities 163.7m)
Debt / Equity = 0.18 (Debt 378.2m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.33 (Net Debt 113.5m / EBITDA 343.4m)
Debt / FCF = 0.43 (Net Debt 113.5m / FCF TTM 263.2m)
Total Stockholder Equity = 2.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.07% (Net Income 181.9m / Total Assets 2.59b)
RoE = 8.90% (Net Income TTM 181.9m / Total Stockholder Equity 2.04b)
RoCE = 10.97% (EBIT 246.1m / Capital Employed (Equity 2.04b + L.T.Debt 200.0m))
RoIC = 7.82% (NOPAT 185.9m / Invested Capital 2.38b)
WACC = 8.79% (E(11.4b)/V(11.8b) * Re(9.01%) + D(378.2m)/V(11.8b) * Rd(2.97%) * (1-Tc(0.24)))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.60 | Cagr: -0.97%
[DCF] Terminal Value 74.25% ; FCFF base≈260.6m ; Y1≈267.3m ; Y5≈295.5m
[DCF] Fair Price = 26.36 (EV 4.25b - Net Debt 113.5m = Equity 4.14b / Shares 157.1m; r=8.79% [WACC]; 5y FCF grow 2.60% → 2.50% )
EPS Correlation: 1.46 | EPS CAGR: 0.05% | SUE: 1.51 | # QB: 1
Revenue Correlation: 92.34 | Revenue CAGR: 2.70% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.45 | Chg30d=+4.48% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-12-31): EPS=0.48 | Chg30d=+1.43% | Revisions=+25% | Analysts=6
EPS current Year (2027-06-30): EPS=2.04 | Chg30d=+0.89% | Revisions=+40% | GrowthEPS=+5.5% | GrowthRev=+4.4%
EPS next Year (2028-06-30): EPS=2.31 | Chg30d=+0.22% | Revisions=+50% | GrowthEPS=+13.5% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +70% (up=7, down=0)